Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Death/hospitalization -30% Death/hospitalization (b) 22% Recovery -6% Dorward et al. Colchicine for COVID-19 RCT LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? RCT 1,301 patients in the United Kingdom (March - May 2021) Lower mortality with colchicine (not stat. sig., p=0.43) Dorward et al., British J. General Practice, doi:10.3399/BJGP.2022.0083 Favors colchicine Favors control
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Dorward et al., British Journal of General Practice, doi:10.3399/BJGP.2022.0083 (date from earlier preprint)
Dorward et al., Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, British Journal of General Practice, doi:10.3399/BJGP.2022.0083 (date from earlier preprint)
Sep 2021   Source   PDF  
  All Studies   Meta
Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. ISRCTN86534580.
risk of death, 69.7% lower, RR 0.30, p = 0.43, treatment 0 of 156 (0.0%), control 1 of 120 (0.8%), NNT 120, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of death/hospitalization, 29.8% higher, RR 1.30, p = 0.66, treatment 6 of 156 (3.8%), control 4 of 133 (3.0%), odds ratio converted to relative risk, concurrent randomisation.
risk of death/hospitalization, 22.1% lower, RR 0.78, p = 0.59, treatment 6 of 156 (3.8%), control 119 of 1,145 (10.4%), odds ratio converted to relative risk, including control patients before the colchicine arm started.
risk of no recovery, 6.4% higher, HR 1.06, p = 0.67, treatment 156, control 133, inverted to make HR<1 favor treatment, time to alleviation of symptoms, concurrent randomisation.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dorward et al., 23 Sep 2021, Randomized Controlled Trial, United Kingdom, peer-reviewed, 21 authors, study period 4 March, 2021 - 26 May, 2021, average treatment delay 6.0 days, dosage 0.5mg days 1-14.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Accepted Manuscript British Journal of General Practice Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial Dorward, Jienchi; Yu, Ly-mee; Hayward, Gail; Saville, Benjamin; Gbinigie, Oghenekome; van Hecke, Oliver; Ogburn, Emma; Evans, Philip; Thomas, Nicholas; Patel, Mahendra; Richards, Duncan; Berry, Nicholas ; Detry, Michelle; Saunders, Christina; Fitzgerald, Mark; Harris, Victoria; Shanyinde, Milensu; de Lusignan, Simon; Andersson, Monique; Butler, Christopher; Hobbs, FD Richard DOI: To access the most recent version of this article, please click the DOI URL in the line above. Received 11 February 2022 Revised 25 February 2022 Accepted 02 March 2022 © 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License ( Published by British Journal of General Practice. For editorial process and policies, see: When citing this article please include the DOI provided above. Author Accepted Manuscript This is an ‘author accepted manuscript’: a manuscript that has been accepted for publication in British Journal of ­General Practice, but which has not yet undergone subediting, typesetting, or correction. Errors discovered and corrected during this process may materially alter the content of this manuscript, and the latest published version (the Version of Record) should be used in preference to any preceding versions Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial PRINCIPLE Trial Collaborative Group¶ ¶Writing committee listed below on behalf of the PRINCIPLE Trial Collaborative Group. PRINCIPLE trial collaborators are listed in the appendix Writing committee Dr Jienchi Dorward (0000-0001-6072-1430)*1,2 clinical research fellow, Prof Ly-Mee Yu (00000003-0331-7364)*1 associate professor, Prof Gail Hayward (0000-0003-0852-627X)1 associate professor, Dr Benjamin R Saville3,4 statistician, Dr Oghenekome Gbinigie (0000-0002-29634491)1 clinical research fellow, Dr Oliver Van Hecke (0000-0002-6229-5057)1 academic clinical lecturer, Dr Emma Ogburn (0000-0001-7643-572X)1 director of operations, Prof Philip H Evans (0000-0002-5277-3545)5,6 associate professor, Dr Nicholas PB Thomas (0000-0003-04606870)6,7 general practitioner, Prof Mahendra G Patel (0000-0001-6703-3542)1 professor, Prof Duncan Richards (0000-0002-8093-7084)8 professor, Dr Nicholas Berry (0000-0001-87013258)3 statistician, Dr Michelle A Detry (0000-0002-2794-1439)3 statistician, Dr Christina Saunders (0000-0003-4325-9568)3 statistician, Dr Mark Fitzgerald (0000-0002-8912-1663)3 statistician, Dr Victoria Harris (0000-0002-3345-2826)1 statistician, Dr Milensu Shanyinde (0000-0003-4842-9247)1 statistician, Prof Simon de Lusignan (0000-0002-8553-2641)1,7 professor, Dr Monique I Andersson (0000-0003-0619-1074)9 consultant, Prof Christopher C Butler professor (0000-0002-0102-3453), 1†Prof FD Richard Hobbs (0000-0001-7976-7172) 1† professor 1 Writing Committee affiliations 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK 2. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu–Natal, Durban, South Africa 3. Berry Consultants, Texas, USA 4. Department of Biostatistics, Vanderbilt University School of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop